Table 5 Treatment dose level, number of cycles administered and full response assessment in patients with newly-diagnosed, previously untreated multiple myeloma enrolled in phase I study of siltuximab in combination with RVD (N=11)
Patient number | Dose level | Number of cycles completed | Response after 4 cycles | ASCT | Response after ASCT at | |
|---|---|---|---|---|---|---|
3 mo. | 6 mo. | |||||
1 | 1 | 9 | VGPR (near CRa) | No (Consent withdrawn—patient moved out of state) | ||
2 | 1 | 4 | VGPR | Yes | Near CR | Near CR |
3 | 1 | 4 | PR | Yes | VGPR | VGPR |
4 | 1 | 4 | PR | Yes | PR | PR |
5 | 1 | 4 | PR | Yes | PR | PR |
6 | 1 | 3 | VGPRb | No (Consent withdrawn due to peripheral neuropathy with pain and edema) | ||
7 | −1 | 4 | PR | Yes | PR | PR |
8 | −1 | 5 | VGPR | Yes | Near CR | CR |
9 | −1 | 4 | VGPR | Yes | VGPR | Near CR |
10 | −1 | 3 | CRb | Yes | Lost to follow-up | |
11 | −1 | 4 | MR | Yes | CR | VGPR |
